EXHIBIT D

Exhibit D to the Greenbaum Declaration

Document Title/ECF No.	Basis for Sealing	Clearly Defined and Serious Injury that Would Result if the Relief is Not Granted	Why a Less Restrictive Alternative to the Relief Sought is Not Available	Any Prior Order Sealing the Same Materials in the Pending Action	Party in Opposition to Sealing, if any, and Basis
Exhibit 1 to Letter dated November 7, 2024 [ECF No. 443]	Exhibit 1 is a letter motion dated May 2, 2024 that was previously the subject of a motion to seal, ECF No 360, *see also* ECF No. 375 (granting motion to seal). Exhibit 1 contains a reference to (1) an allegation made by Johnson & Johnson Healthcare Systems Inc. ("J&J") about Save On SP, LLC's ("SaveOn") business strategy, the basis for which J&J learned during discovery from SaveOn's internal emails, and (2) an email produced during discovery from a SaveOn employee discussing SaveOn's business strategy, both comprising proprietary business	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants.	A redacted, public version of the Letter is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	Yes, *see* ECF No. 375; *see also* ECF No. 418 (redacted version).	No objection

	information. *See* ECF No. 443 Ex. 1.				
Exhibit 3 to Letter dated November 7, 2024 [ECF No. 443]	Exhibit 3 is a letter motion dated May 9, 2024 that was previously the subject of a motion to seal, ECF No 360, *see also* ECF No. 375 (granting motion to seal). Exhibit 3 contains discussion of SaveOn's business model and financial relationship with its clients, comprising proprietary business information. *See* ECF No. 443 Ex. 3.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants.	A redacted, public version of the Letter is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	Yes, *see* ECF No. 375; *see also* ECF No. 418 (redacted version).	No objection
Exhibit 4 to Letter dated November 7, 2024 [ECF No. 443]	Exhibit 4 is a transcript of a hearing held in front of Judge Wolfson on May 23, 2024 concerning multiple discovery motions between SaveOn and J&J. The transcript contains discussion of SaveOn's business practices and revenue, disclosed to J&J during discovery and comprising confidential business information. *See* ECF No. 443 Ex. 4.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants.	A redacted, public version of the transcript is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No.	No objection

2

| Exhibit 6 to Letter dated November 7, 2024 [ECF No. 443] | Exhibit 6 is a transcript of a hearing held in front of Judge Wolfson on April 3, 2024 concerning multiple discovery motions between SaveOn and J&J. The transcript contains discussion of SaveOn's internal confidentiality policy and practices for enforcing it, comprising confidential business information. *See* ECF No. 443 Ex. 6. | If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants. | A redacted, public version of the transcript is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information. | No. | No objection |

3